TRAVERE THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M | $198.3M | $175.3M | $164.2M |
| Cost of Revenue | $10.3M | $7.7M | $11.5M | $4.4M | $3.8M | $6.1M | $5.2M | $5.5M |
| Gross Profit | $480.4M | $225.4M | $133.8M | $105.0M | $128.0M | $192.2M | $170.1M | $158.7M |
| Gross Margin | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | 96.9% | 97.0% | 96.6% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | $7.5M | — | — | $141.0M | $123.8M |
| SG&A Expense | $337.2M | $264.1M | $265.5M | $197.5M | $126.3M | $135.8M | $129.0M | $103.7M |
| Operating Income | $-62.8M | $-323.8M | $-388.1M | $-319.8M | $-199.4M | $-176.2M | $-137.4M | $-80.0M |
| Operating Margin | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% | -88.8% | -78.3% | -48.7% |
| Interest Expense | — | — | $11.3M | $11.0M | $19.7M | $19.1M | $18.8M | $9.8M |
| Pretax Income | $-49.3M | $-320.5M | $-376.1M | $-331.2M | $-216.9M | $-188.8M | $-146.4M | $-101.9M |
| Income Tax Expense | $988.0K | $120.0K | $223.0K | $313.0K | $409.0K | $-19.4M | $-21.0K | $811.0K |
| Net Income | $-25.5M | $-321.5M | $-111.4M | $-278.5M | $-180.1M | $-169.4M | $-146.4M | $-102.7M |
| Net Margin | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | -85.4% | -83.5% | -62.5% |
| EPS (Basic) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 | $-3.46 | $-2.54 |
| EPS (Diluted) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 | $-3.46 | $-2.54 |
| Shares Outstanding (Basic) | 89.2M | 78.9M | 74.3M | 63.8M | 59.8M | 47.5M | 42.3M | 40.4M |
| Shares Outstanding (Diluted) | 89.2M | 78.9M | 74.3M | 63.8M | 59.8M | 47.5M | 42.3M | 40.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |